Axitinib D3
| Product Name | Axitinib D3 |
|---|---|
| Alternate Names | Axitinib Stable Isotopes, Stable Isotopes of Axitinib |
| CAT No. | CS-O-14379 |
| CAS No. | 1126623-89-9 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 389.49 g/mol |
| Mol. For. | C₂₂H₁₅D₃N₄OS |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Axitinib |
| Purity | Not less than 90 % |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | O=C(NC([2H])([2H])[2H])C1=C(C=CC=C1)SC2=CC=C3C(/C=C/C4=CC=CC=N4)=NNC3=C2 |
| Canonical Smiles | CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4 |
| InchIKey | RITAVMQDGBJQJZ-VOTVRPQJSA-N |
| Inchl | InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+/i1D3 |
| IUPAC | 2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]-N-(trideuteriomethyl)benzamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Axitinib D3 is a deuterated version of Axitinib, which is a potent inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. It is primarily used as a targeted therapy for the treatment of advanced renal cell carcinoma, which is a type of kidney cancer. Axitinib D3 works by blocking the proteins that help cancer cells grow and form new blood vessels, which are necessary for their survival and spread throughout the body.
The chemical structure of Axitinib D3 is similar to that of Axitinib, with the addition of three deuterium atoms. Deuterium is a stable isotope of hydrogen that has a higher atomic mass, which can result in slower metabolism and longer half-life in the body. This modification can potentially improve the pharmacokinetics and efficacy of Axitinib D3, as well as reduce potential side effects.
Axitinib D3 is administered orally in the form of tablets, usually twice a day with or without food. The dosage may vary depending on the patient's medical condition, body weight, and other factors. It is important to follow the prescribed regimen and notify the healthcare provider of any adverse reactions or interactions with other medications.
In summary, Axitinib D3 is a deuterated version of Axitinib that is used as a targeted therapy for the treatment of advanced renal cell carcinoma. It works by blocking the growth and spread of cancer cells by inhibiting vascular endothelial growth factor receptors. The addition of deuterium atoms can potentially improve the pharmacokinetics and efficacy of Axitinib D3.
Get an Instant Quote
Related Compounds
Axitinib 13C D3 | Axitinib-D3 Hydrate |